Belpointe Asset Management LLC Buys Shares of 1,952 Allergan PLC. (AGN)

Belpointe Asset Management LLC bought a new stake in shares of Allergan PLC. (NYSE:AGN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,952 shares of the company’s stock, valued at approximately $400,000.

A number of other hedge funds have also added to or reduced their stakes in AGN. Portland Global Advisors LLC raised its holdings in shares of Allergan by 1.8% during the second quarter. Portland Global Advisors LLC now owns 7,721 shares of the company’s stock valued at $1,877,000 after acquiring an additional 140 shares during the period. Laurel Grove Capital LLC raised its holdings in shares of Allergan by 6.2% during the second quarter. Laurel Grove Capital LLC now owns 12,178 shares of the company’s stock valued at $2,960,000 after acquiring an additional 713 shares during the period. Confluence Investment Management LLC raised its holdings in shares of Allergan by 10.9% during the second quarter. Confluence Investment Management LLC now owns 295,395 shares of the company’s stock valued at $71,807,000 after acquiring an additional 29,058 shares during the period. Pennsylvania Trust Co raised its holdings in shares of Allergan by 332.0% during the second quarter. Pennsylvania Trust Co now owns 30,105 shares of the company’s stock valued at $7,318,000 after acquiring an additional 23,137 shares during the period. Finally, Bank of The West raised its holdings in shares of Allergan by 4.1% during the second quarter. Bank of The West now owns 20,746 shares of the company’s stock valued at $5,044,000 after acquiring an additional 809 shares during the period. 81.34% of the stock is owned by institutional investors and hedge funds.

Allergan PLC. (NYSE AGN) opened at $171.68 on Friday. The firm has a market cap of $56,851.75, a P/E ratio of 11.09, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. Allergan PLC. has a 12 month low of $160.07 and a 12 month high of $256.80.

Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.32 EPS. equities research analysts expect that Allergan PLC. will post 16.27 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, November 17th were paid a $0.70 dividend. The ex-dividend date of this dividend was Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.63%. Allergan’s dividend payout ratio is presently -12.44%.

Allergan announced that its board has approved a stock buyback program on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

A number of research firms have recently issued reports on AGN. Cantor Fitzgerald set a $191.00 price target on shares of Allergan and gave the company a “hold” rating in a report on Tuesday. Morgan Stanley set a $200.00 price target on shares of Allergan and gave the company a “buy” rating in a report on Wednesday, December 6th. Wells Fargo & Company restated a “buy” rating on shares of Allergan in a report on Wednesday, December 6th. Mizuho restated a “buy” rating and set a $267.00 price target on shares of Allergan in a report on Monday, September 25th. Finally, Barclays restated an “equal weight” rating on shares of Allergan in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $235.25.

In other Allergan news, Chairman Brent L. Saunders bought 4,600 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was bought at an average cost of $164.74 per share, with a total value of $757,804.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last quarter, insiders acquired 17,630 shares of company stock worth $2,890,057. Company insiders own 0.36% of the company’s stock.

WARNING: “Belpointe Asset Management LLC Buys Shares of 1,952 Allergan PLC. (AGN)” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/16/belpointe-asset-management-llc-buys-shares-of-1952-allergan-plc-agn.html.

Allergan Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit